确定PRDX5作为治疗割抵抗性前列腺癌的标
Rong Wang1,2, Yuanyuan Mi3, Jiang Ni3
1Jiangnan University Medical Center, Jiangnan University, Wuxi, 214002, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 20, 2023
概括
雄激素受体 (AR) 抑制剂治疗导致割抵抗性前列腺癌 (CRPC) 中的耐药性持续性 (DTP) 状态. 抑制Peroxiredoxin 5 (PRDX5) 抑制DTP细胞和CRPC进展,提供了一个新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 抗割前列腺癌 (CRPC) 是一个重大的临床挑战.
- 目前的治疗方法针对二测试生物合成或雄激素受体 (AR) 信号.
研究的目的:
- 研究CRPC中AR抑制剂治疗的耐药性机制.
- 确定用于管理CRPC的新型治疗点.
主要方法:
- 在CRPC细胞中诱导一种耐药性持久性 (DTP) 状态.
- 在DTP细胞中分析硫素/氧素通路.
- 在体外和体外模型中抑制百氧化素5 (PRDX5).
- 对患者瘤进展的PRDX5抑制的评估.
主要成果:
- 治疗AR抑制剂导致DTP状态的出现.
- 硫素/氧素通路,特别是PRDX5,在DTP细胞中被上调.
- 抑制PRDX5抑制了DTP细胞增殖,动物模型中的CRPC发育,并稳定了患者的PSA进展和转移性病变.
结论:
- 在促进AR抑制剂耐药性和CRPC进展方面,PRDX5起着至关重要的作用.
- 向PRDX5代表了CRPC管理的新型治疗策略.
更多相关视频
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K